亞盛醫藥-B(06855.HK)推進單藥或聯合治療晚期 ER+ 乳腺癌或實體瘤的臨床開發 1970-01-01T00:00:00-05:00January 1st, 1970| share this article!【財華社訊】亞盛醫藥-B(06855.HK)公布,公司在研原創新藥Bcl-2抑制劑APG-2575的臨床試驗申請獲美國食品藥品管理局(美國FDA)許可,將展開單藥或與抗癌藥物聯合治療晚期ER+乳腺癌或實體瘤的研究。 Read More share this article! Related Posts Hiroshima company’s ‘forever’ usable laundry equipment spurs growth May 4th, 2024 Boom in data centers challenges clean power goals in Asia May 4th, 2024 New ‘Detective Conan’ movie puts supporting characters in the limelight May 4th, 2024 China’s TikTok Shop sellers brace for an uncertain future May 4th, 2024